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Age-related macular degeneration (AMD) is a complex multifactorial degenerative disease
that leads to irreversible blindness. AMD affects the macula, the central part of the retina
responsible for sharp central vision. Retinal pigment epithelium (RPE) is the main cellular
type affected in dry AMD. RPE cells form a monolayer between the choroid and the
neuroretina and are in close functional relationship with photoreceptors; moreover, RPE
cells are part of the blood retina barrier that is disrupted in ocular diseases such as AMD.
During ocular inflammation lymphocytes andmacrophages are recruited, contact RPE and
produce pro-inflammatory cytokines, which play an important role in AMD pathogenesis.
The interaction between RPE and immune cells is mediated by leukocyte integrins,
heterodimeric transmembrane receptors, and adhesion molecules, including VCAM-1
and ICAM-1. Within this frame, this study aimed to characterize RPE-leukocytes
interaction and to investigate any potentially beneficial effects induced by integrin
antagonists (DS-70, MN27 and SR714), developed in previous studies. ARPE-19 cells
were co-cultured for different incubation times with Jurkat cells and apoptosis and
necrosis levels were analyzed by flow cytometry. Moreover, we measured the mRNA
levels of the pro-inflammatory cytokine IL-1β and the expression of adhesion molecules
VCAM-1 and ICAM-1. We found that RPE-lymphocyte interaction increased apoptosis
and necrosis levels in RPE cells and the expression of IL-1β. This interaction was mediated
by the binding of α4β1 and αLβ2 integrins to VCAM-1 and ICAM-1, respectively. The
blockade of RPE-lymphocyte interaction with blocking antibodies highlighted the pivotal
role played by integrins. Therefore, α4β1 and αLβ2 integrin antagonists were employed to
disrupt RPE-lymphocyte crosstalk. Small molecule integrin antagonists proved to be
effective in reducing RPE cell death and expression of IL-1β, demonstrating that integrin
antagonists could protect RPE cells from detrimental effects induced by the interaction
with immune cells recruited to the retina. Overall, the leukocyte integrin antagonists
employed in the present study may represent a novel opportunity to develop new
drugs to fight dry AMD.
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INTRODUCTION
Age-related macular degeneration (AMD) is a progressive
degenerative disease that leads to irreversible blindness in
elderly people (Akyol and Lotery, 2020). AMD affects the
macula, the ocular region responsible for sharp central vision.
Two forms of AMD have been described: dry AMD is the most
common type of the disease and causes atrophic degeneration of
the macula leading to gradual vision loss (advanced AMD or
geographic atrophy). On the contrary, wet AMD is characterized
by choroidal neovascularization (CNV) that rapidly causes
blindness (Ambati and Fowler, 2012). Since vascular
endothelial growth factor (VEGF) is a predominant
proangiogenic factor in CNV, wet AMD can be treated with
intravitreous administration of anti-angiogenic agents such as
aflibercept and ranibizumab (Supuran, 2019). Conversely, there is
currently no effective pharmacological treatment for “dry” AMD
although novel therapeutic strategies are under development
(Akyol and Lotery, 2020). The pathogenesis of dry AMD is
not completely understood and involves a complex interplay
among several mechanisms. Oxidative stress, together with
other factors, including aging, genetic factors, phototoxicity,
complement system activation, can lead to retinal pigment
epithelium (RPE) degeneration and photoreceptors death, and
can raise in immune response and inflammation (Strauss, 2005;
Hanus et al., 2015). RPE is a monolayer of cells embedded
between the choroid and the neuroretina. Normal
physiological functions of RPE cells are important for outer
retina homeostasis and for normal vision. One of the late
events in AMD pathogenesis is RPE cell death, associated with
the degradation of the overlying photoreceptors and the
underlying choriocapillaris (Van Lookeren Campagne et al.,
2014). In addition, RPE is a component of the blood-retina
barrier (BRB) limiting the penetration of blood components to
the retina and is also implicated in the recruitment of immune
cells during local inflammation. During ocular inflammatory
process lymphocytes and macrophages are recruited to the
posterior compartment of the eye and produce pro-
inflammatory cytokines, including tumor necrosis factor α
(TNFα), interleukin-1β (IL-1β) and IL-6 (Cousins et al., 2004),
which play an important role in AMD pathogenesis. Adhesion
molecules, such as intercellular adhesion molecules-1 (ICAM-1)
and vascular cell adhesion molecule-1 (VCAM-1) mediate
leukocyte adhesion and recruitment to RPE. Cultured RPE
cells constitutively express ICAM-1 but not VCAM-1; both
adhesion molecules are upregulated after treatment with pro-
inflammatory cytokines (Platts et al., 1995). Adhesion molecules
are physiological ligands of integrins, heterodimeric
transmembrane proteins formed by non-covalent association
of α and β subunit (Tolomelli et al., 2017; Baiula et al., 2019).
Notably, leukocyte integrins, including α4β1 and αLβ2, mediate
immune cell recruitment to inflamed tissue. Some agents
targeting integrins have already been approved for clinical
practice (Raab-Westphal et al., 2017) and several new ligands
are presently under development.
Within this frame, in previous studies, we investigated new
ligands targeting different types of integrin (DeMarco et al., 2015;
Tolomelli et al., 2015; Baiula et al., 2016; Baiula et al., 2020; Dattoli
et al., 2018; Martelli et al., 2019). In particular, we identified
MN27, SR714, and DS-70 as potent and selective leukocyte
integrin antagonists able to significantly reduce integrin-
mediated cell adhesion and intracellular signaling activation in
a concentration-dependent manner (Baiula et al., 2016; Dattoli
et al., 2018). Therefore, considering integrins as a valuable drug
target, the current study was designed to elucidate the crosstalk
between RPE and leukocytes in vitro and to characterize any
potentially beneficial effects induced by integrin antagonists
within this frame. To this purpose ARPE-19 cells were co-
cultured with immune cells for different time points and we
analyzed apoptosis and necrosis levels, adhesion molecule
expression, integrin-mediated cell adhesion, intracellular
signaling activation and IL-1β expression. Moreover, we
investigated the effects of integrin antagonists on RPE-
leukocytes interaction. We found that integrin antagonists
were able to disrupt RPE-immune cell interaction leading to
reduced RPE cell death. Therefore, our results open up the
possibility to exploit integrin antagonists as innovative
therapeutics to fight dry AMD.
MATERIALS AND METHODS
Cell Culture and Treatments
ARPE-19 cells (American Type Culture Collection, ATCC,
Rockville, MD; passages 4–7), a human spontaneously arising
retinal pigment epithelia cell line, were grown in Dulbecco’s
modified Eagle’s medium and Ham’s F12 medium (DMEM/
F12, Life Technologies, Monza, Italy) supplemented with 10%
fetal bovine serum (FBS, Life Technologies) and antibiotic-
antimycotic solution (Life Technologies). Jurkat E6.1 cells
(ATCC; passages 5–10) were cultured in RPMI 1640 (Life
Technologies) supplemented with 2 mM glutamine, 10% FBS
and antibiotic-antimycotic solution. Cells were cultured at 37°C
under 5% CO2 humidified atmosphere.
To study ARPE-19-Jurkat cells interactions, ARPE-19 cells
were seeded in 6-well plates and cultured until monolayers were
formed. Then, Jurkat cells (106 cells/well) were added and co-
cultured with ARPE-19 cells for different incubation periods (1,
16, 24 and 48 hours). ARPE-19-Jurkat co-culture were performed
in the presence of 1 mM Mn2+ to ensure integrin activation and
high affinity ligand binding. At the end of the co-culture, immune
cells were removed by washing the wells three times with PBS
(phosphate buffered saline, Life Technologies) and ARPE-19 cells
were detached with Trypsin/EDTA 1% solution (Lonza). Finally,
cells were centrifuged separately and pelleted to be stored at -80°
for further analyses.
Neutralizing antibodies anti-VCAM-1 (clone 51-10C9, cat.
n.555645) or anti-ICAM-1 (clone LB-2, cat. n.559047) (both from
BD Pharmingen™) were added to ARPE-19 cells at saturation
concentration (10 μg/mL) for one hour before the addition of
Jurkat cells; alternatively, Jurkat cells were pre-incubated with
anti-α4 integrin (10 μg/mL, clone 44H6, cat. n. ab220, Abcam) or
anti-αL (clone HI111, cat. n.555381, BD Pharmingen) for 1 h
before being overlaid on ARPE-19 cells. Thereafter, the co-culture
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was extended for 24 hours. Cells were collected separately and
stored as above described.
Integrin antagonists employed in this study have been
previously investigated (Baiula et al., 2016; Dattoli et al.,
2018). These compounds had displayed a strong antagonist
activity against αLβ2 (MN27) or α4β1 (DS-70 and SR714)
integrins (Table 1). A stock solution (10−2 M) of integrin
antagonists was prepared in dimethyl sulfoxide (DMSO,
vehicle) and its final concentration did not exceed 0.1%; an
equal volume of vehicle was added as control to vehicle cells.
Cells were pre-incubated with different concentrations
(1–100 nM) of integrin antagonists for 30 min at 37°C before
adding Jurkat to ARPE-19 cells for 24 hours.
Adhesion Assay
ARPE-19 cells were plated in black 96-well plates (15000 well)
and grown for 24–48 h. ARPE-19 cells were pretreated with or
without anti-ICAM-1 or anti-VCAM-1 antibodies (10 μg/mL) for
1 h. Jurkat cells (50000 cells/well) were labelled with Cell Tracker
green CMFDA (12.5 μM, 30 min at 37°C, Life Technologies) and,
after three washes with PBS, were overlaid on ARPE-19 cells; the
cells were incubated at 37°C for 3 h. Then, after three gently
washes with PBS to remove nonadherent Jurkat cells, the
remaining cells were lysed with 0.5% Triton X-100 in PBS (for
30 min at 4°C). The number of fluorescently labeled adherent
Jurkat cells was determined measuring fluorescence (Ex485 nm/
Em535 nm) in an EnSpire Multimode Plate Reader (PerkinElmer,
Waltham, MA, USA). The number of adherent cells was
determined by comparison with a standard curve built up in
the same plate with known numbers of labelled Jurkat cells. To
investigate the role of integrins in ARPE-19-Jurkat interactions,
Jurkat cells were pre-incubated with 10 μg/mL of anti-α4β1
integrin or anti-αL antibody for 1 h. In another set of
experiment, Jurkat cells were exposed to increasing
concentrations (1–100 nM) of integrin antagonists (DS-70,
MN27 or SR714) for specified times.
Apoptosis Detection
Apoptosis was analyzed by flow cytometry as previously
described (Baiula et al., 2016; Dattoli et al., 2018).
Phycoerythrin-conjugated annexin V (annexin V-PE) and 7-
amino-actynomicin D (7-AAD; Guava Nexin Reagent,
Millipore, Darmstadt, Germany) were employed to determine
the percentage of viable, early apoptotic and late apoptotic/
necrotic cells by flow cytometry. ARPE-19 and Jurkat cells
were co-cultured for different time points and then cells were
collected separately by centrifugation and resuspended in 100 μL
of complete medium. For apoptosis/necrosis staining, 100 μL of
Nexin reagent were added and ARPE-19 and Jurkat cells were
incubated for 20 min at room temperature in the dark, following
manufacturer’s instructions. Thereafter, cells were analyzed on a
Guava EasyCyte 5 flow cytometer (Millipore); at least 10000 cells/
sample were acquired. Three populations of cells can be identified
by this assay: viable cells (annexin V-PE and 7-AAD negative),
early apoptotic cells (annexin V-PE positive and 7-AAD
negative), and late stage apoptosis or necrotic cells (annexin
V-PE and 7-AAD positive).
Flow Cytometry
To evaluate expression of integrins and adhesion molecules on
ARPE-19 cells, anti-ICAM-1, anti-VCAM-1, anti-α5 (clone VC5,
cat. n.555651, BD Pharmingen), anti-αM (clone M1/70, cat. n.
MAB1387Z, Chemicon International), anti-αL (clone HI111, cat.
n.555381, BD Pharmingen), anti-β1 (clone HUTS-21, cat. n.
556049, BD Pharmingen), anti-β2 (clone 6.7, cat. n. 555923,
BD Pharmingen), or anti-α4 monoclonal antibody (cat. n.
ab202969, Abcam), were used in 1% BSA/HBSS (Hanks’
Balanced Salt Solution, Life Technologies) for 45 min at 4°C.
After two washes in 1% BSA/HBSS cells were incubated with goat
anti-rabbit IgG (H + L) secondary antibody, Alexa Fluor 488 in
1% BSA/HBSS (Life Technologies) for 45 min at 4°C. After two
washes with 1% BSA/HBSS, cells were resuspended in PBS and
analyzed at Guava® EasyCyte™ flow cytometer (Millipore) and at
least 10000 cells/sample were analyzed. Evaluation of the relative
fluorescence for nonspecific binding by exposing the cells to an
isotype control monoclonal antibody FITC mouse IgG (BD
Pharmingen) was done for data normalization (Dattoli et al.,
2018).
Real Time RT-PCR
At the end of the co-culture, ARPE-19 and Jurkat cells were
collected separately as described above and centrifuged (500 g for
5 min). PD 98059 (10 μM, 30 min; Sigma Aldrich), a non-
competitive blocker of ERK1/2 activation (Di Toro et al., 2005;
Baiula et al., 2012) was used to investigate the role of integrin-
mediated ERK1/2 signaling. Total cellular RNA was extracted
with Trireagent® (Sigma-Aldrich, Milan, Italy) and digested with
Rnase-free Dnase (Thermo Fisher Scientific, Walthman, MA,
TABLE 1 | Solid-phase, SPA binding and inhibition of cell adhesion of integrin antagonists MN27, DS-70 and SR714 to VCAM-1 or ICAM-1 (2 μg/mL) (Baiula et al., 2016;
Dattoli et al., 2018).






MN27 (αLβ2) 6.7 ± 2.5 (αLβ2) 574.0 ± 1.7 0.39 ± 0.02
DS-70 (α4β1) 8.3 ± 3.2 (α4β1) 5.04 ± 0.51 >5000
SR714 (α4β1) 1.1 ± 0.1 (α4β1) 1.39 ± 0.04 >5000
aIC50 values of β-lactam compounds and DS-70 on leukocyte integrins determined by a competitive solid-phase binding assay to specific ligand (ICAM-1 for αLβ2) or by scintillation
proximity assay (SPA, FN for α4β1). Six independent experiments were run in quadruplicate. Data are expressed as means ± SD (Baiula et al., 2016; Dattoli et al., 2018).
bIn a cell-based assay, the adhesion of a cell line preferentially expressing a specific integrin heterodimer to an immobilized adhesionmolecule wasmeasured. Six independent experiments
were run in quadruplicate. Data are expressed as means ± SD (Baiula et al., 2016; Dattoli et al., 2018).
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USA) for 15 min at 25°C. High Capacity cDNA reverse
transcription kit (Life Technologies) was used to reverse
transcribe a 2-µg sample, according to the manufacturer’s
instructions. Relative quantification of human IL-1β transcripts
was performed by Real-Time PCR using the StepOne Instrument
(Life Technologies). The GoTaq® qPCR master mix (Promega,
Madison, Wisconsin, USA) was chosen to perform the reaction as
follow: denaturation at 95°C for 10 min, followed by 40 cycles of
95°C for 30 sec, 68°C for 30 sec and 72°C for 30 sec. To amplify
human IL-1β cDNA, a sense primer (5′-CAAGGGCTTCAG
GCAGGCCG-3′) and an antisense primer (5′-TGAGTCCCG
GAGCGTGCAGT-3′) were used at 0.25 µM concentration for
producing a 213-bp fragment (261–474 bp; GenBank Accession
no. NM_000576.2). As a control, a 169-bp fragment of the human
L19 ribosomal protein gene (62–230 bp; GenBank Accession No.
BC062709) was amplified with a sense primer (5′-CTAGTGTCC
TCCGCTGTGG-3′) and an antisense primer (5′-AAGGTGTTT
TTCCGGCATC-3′) at 0.25 µM concentration (Bedini et al.,
2017). No-template controls and DNA melting curve analysis
were employed as controls. Relative expression of RT-PCR
products was determined using the ΔΔCt method (Winer et
al., 1999). Each sample was run in triplicate and L19 was
chosen for normalization because of its consistent expression
relative to other housekeeping genes among the experimental
groups in our study.
Western Blot Analysis
Western blot analysis was performed as previously described
(Dattoli et al., 2018) with the following modifications. Briefly,
ARPE-19 cells were plated into 60 mm dishes until a confluence
of 80–90% was reached; the cells were incubated with Jurkat cells
(106 cells/well) as described in a previous section. Thereafter, the
cells were homogenized in lysis buffer (50 mMTris-HCl, 300 mM
NaCl, 1 mMEDTA, 1 mMNa3VO4, 1 mMNaF, 10% glycerol, 1%
Triton-X 100) supplemented with phosphatase inhibitor and
protease inhibitor cocktail (both 1:100, Sigma-Aldrich SRL).
The homogenates were sonicated for 10 sec and then
centrifuged at 17000 g for 25 minutes at 4°C; protein
concentration was determined by BCA assay (Pierce,
Rockford, IL, USA). Protein extracts (15 µg) were denatured at
95°C for 3 min and separated by 12% SDS-PAGE. The
membranes were blocked in 5% BSA in TBS-T (20 mM Tris-
HCl, pH 7.5, 137 mM NaCl, 0.1 (v/v) % Tween 20) for 1 h and
incubated with anti-phospho-ERK 1/2 (extracellular signal-
regulated kinase 1/2, 1:1000; Cell Signaling Technology,
Danvers, MA, USA) or anti-total ERK1/2 antibodies (1:1000;
Cell Signaling Technology) overnight at 4°C. Subsequently, the
membranes were incubated with peroxidase-conjugated anti-
rabbit secondary antibodies at a 1:8000 dilution (Santa Cruz
Biotechnology, Dallas, Texas, USA) at room temperature for
1.5 h. Digital images were acquired and analyzed according to
a previously reported method (Bedini et al., 2008). Experiments
were replicated independently at least four times.
Statistical Analysis
All data are presented as the mean ± SD for the number of
experiments reported. Statistical comparisons were performed
using one-way ANOVA followed by Newman-Keuls test
(GraphPad Prism, version 5.0; GraphPad Software, Inc., La
Jolla, CA, USA). Statistical significance is stated as p < 0.05.
RESULTS
Characterization of ARPE-19-Jurkat cells
Interaction
Infiltration of mononuclear cells in the outer blood–retina
barrier has been associated to several retinal diseases,
including AMD (Gehrs et al., 2006). Moreover, RPE-to-
immune cells contact and RPE apoptosis/necrosis were
observed within AMD lesions (Ge-Zhi et al., 1996). Key
mechanisms of RPE loss during AMD are both apoptosis
and necrosis (Yang et al., 2011; Hanus et al., 2015). To
evaluate the effects of RPE-immune cells interaction on
apoptosis and necrosis, Jurkat cells were overlaid on ARPE-
19 cells for different time points (1, 16, 24 and 48 h); thereafter,
immune cells were removed by washing with PBS and collected
by centrifugation, whereas ARPE-19 cells were detached by
trypsinization and then centrifugated. Apoptosis/necrosis
levels were evaluated by Annexin V assay as described in the
methods section. Interactions between ARPE-19 and Jurkat
cells led to a significant increase of apoptosis and necrosis in
ARPE-19 cells (Figure 1). Increment in apoptosis and necrosis
in ARPE-19 cells were observed after 16 h of co-culture and
maintained up to 48 h. As regards immune cells, co-cultured
with RPE for different incubation times, no significant changes
of apoptosis or necrosis were found, as shown in Figure 1
(panels C and D). Representative apoptosis/necrosis cytograms
are shown in Supplementary Figure S1.
Adhesion molecules, such as ICAM-1 and VCAM-1, are
endothelial- and leukocyte-associated membrane receptors
playing a pivotal role in cell-cell interactions and in
leukocyte transmigration across the endothelium. Both
ICAM-1 and VCAM-1 are expressed on RPE cells
(Holtkamp et al., 2001; Zhu et al., 2016) and can mediate
RPE-leukocyte interaction. Thus, to determine the role of
adhesion molecules in RPE-immune cells interaction in our
in vitro model, expression levels of ICAM-1 and VCAM-1
were evaluated in both ARPE-19 and Jurkat cells at different
co-culture intervals (1, 16, 24 and 48 h) by flow cytometry. In
ARPE-19 cells VCAM-1 displayed low basal expression levels
that were not altered at any of the considered time points
following co-culture with Jurkat cells (Figure 2A). On Jurkat
cells, expression of VCAM-1 expression was very low and was
not significantly modified by interaction with ARPE-19 cells
(Figure 2C). Similarly, we did not observe any changes in
ICAM-1 levels on Jurkat cells after co-culturing them with
ARPE-19 cells, although this adhesion molecule displayed
higher basal expression levels on Jurkat cells as compared
to VCAM-1 (Figure 2D). On the contrary, ARPE-19 cells
displayed very high levels of ICAM-1 on their cell membrane;
notably, ICAM-1 expression in ARPE-19 was significantly
decreased by the interaction with Jurkat cells starting the
effect after 1 h of co-culture and lasting up to 48 h of ARPE-
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19-Jurkat co-culture (Figure 2B). Representative histograms
of VCAM-1 and ICAM-1 levels in both ARPE-19 and Jurkat
cells are shown in Supplementary Figure S2.
MAPK ERK1/2 signaling is one of the most widely
investigated intracellular pathway with regard to integrins
and adhesion molecules (Hubbard and Rothlein, 2000; Cox
et al., 2006; Meldolesi, 2016). Therefore, we analyzed ERK1/2
activation during ARPE-19-Jurkat co-culture. As shown in
Figure 3, we observed a significant increase of ERK1/2
phosphorylation, evidence of ERK1/2 signaling activation,
both in ARPE-19 and in Jurkat cells throughout co-culture
duration. The interaction between RPE and immune cells led to
a fast activation of ERK1/2 in ARPE-19 cells: accordingly,
ERK1/2 phosphorylation increment was observed after 1 h of
co-culture and was sustained up to 48 h (Figure 3A,B). In
Jurkat cells, phosphorylation of ERK1/2 was significantly
increased after 16 and 24 h of co-culture with ARPE-19 cells
(Figures 3C,D).
Increased levels of inflammatory cytokines are detected in
the eye of patients affected by AMD (Jonas et al., 2012). IL-1β is
a pro-inflammatory cytokine that can be produced and released
from different cells types. To evaluate changes in IL-1β
expression during RPE-immune cells interaction, Jurkat cells
were overlaid on ARPE-19 cells and co-cultured for different
incubation times (1, 16, 24, 48 h). We observed a significant
increment of IL-1β mRNA levels in ARPE-19 cells after 16 h
and up to 48 h of co-culture with Jurkat cells (Figure 4A). In
addition, ARPE-19-Jurkat interactions induced increased levels
of IL-1β also in Jurkat cells after 24 and 48 h of co-culture
(Figure 4B).
Figure 1 | ARPE-19-Jurkat cells co-culture resulted in increased apoptosis and necrosis. Interactions between ARPE-19 and Jurkat cells induced a significant
increase of apoptosis (A) and necrosis (B) in ARPE-19 cells after 16 h of co-culture and up to 48 h. No significant changes in apoptosis (C) or necrosis (D)was observed
in Jurkat cells incubated with ARPE-19 for different time points (0–48 h). Cells not co-cultured were considered as reference (shown as ARPE-19 or Jurkat in the figure).
Apoptosis and necrosis were measured by flow cytometry and the results are presented as the percentage of early apoptotic and late apoptotic/necrotic cells.
Values are mean ± SD from four experiments conducted in triplicate. *p < 0.05; **p < 0.01 vs ARPE-19/Jurkat (Newman-Keuls test after ANOVA).
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Integrins and Adhesion Molecules are
Involved in ARPE-19-Jurkat Cell
Interactions
In previous studies the expression of integrins and adhesion
molecules on RPE has been described (Holtkamp et al., 2001;
Elner et al., 2003; Bian et al., 2018); therefore, to confirm those
results in our in vitro model, integrin expression on ARPE-19
cells was quantified by flow cytometry. High levels of α5
integrin, VCAM-1 and ICAM-1 were observed for ARPE-19
cells (Figures 2, 5A; see also Supplementary Figure S3). On the
contrary, only low amounts of α4, αL, αM, β1, β2 subunits were
detectable on the surface of ARPE-19 cells (Figure 5A). Jurkat
cells are considered a suitable cell model to study integrins and
integrin-mediated cell adhesion and they express mainly α4β1
and αLβ2 integrins (Tolomelli et al., 2015; Dattoli et al., 2018).
To demonstrate the important role played by integrins and
adhesion molecules into the cross-talk between RPE and
leukocytes, Jurkat cells were pre-treated with a neutralizing
anti-α4β1 or anti-αLβ2 integrin antibodies, whereas ARPE-19
cells were pre-incubated with anti-ICAM-1 or anti-VCAM-1
blocking antibody for 1 h. All the antibodies were added at
saturating concentration (10 μg/mL). After pre-treating cells
with the above listed antibodies, ARPE-19 and immune cells
were co-cultured for 24 h; afterwards, cells were collected for
further analysis. Integrins and adhesion molecules expressed
on ARPE-19 and Jurkat cells strongly mediated cell adhesion as
shown Figure 5B. Neutralizing antibodies against adhesion
molecules (VCAM-1 and ICAM-1) or α4 and αL integrin
significantly reduced Jurkat cell adhesion to ARPE-19 cells
(Figure 5B). Moreover, blocking adhesion molecules or
integrins using mAbs led to the disruption of ARPE-19-
Figure 2 | Evaluation of ICAM-1 and VCAM-1 expression levels on ARPE-19 and Jurkat cells co-cultured for different time points (0–48 h). VCAM-1 expression was
not influenced in both ARPE-19 (A) and Jurkat (C) cells. The interactions between ARPE-19 and Jurkat cells induced a significant reduction of ICAM-1 levels expressed
on ARPE-19 cells at all time point considered (B), whereas no changes were measured in ICAM-1 levels on Jurkat cells (D). Data are expressed as mean fluorescence
intensity (MFI) ± SD of four independent experiments carried out in triplicate. MFI values for respective isotype control mAb were set to 0. ***p < 0.001 versus ARPE-
19 (Newman−Keuls test after ANOVA).
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Jurkat interactions and to the blockade of integrin-mediated
signaling activation (Figure 5). Accordingly, neutralizing
antibodies against VCAM-1, ICAM-1 or α4 and αL were able
to prevent ERK1/2 phosphorylation induced by ARPE-19-
Jurkat interaction within 24 h-long co-culture. Control
experiments showed that mAbs were not able to activate
ERK1/2 signaling pathway in ARPE-19 cells not cultured
together with Jurkat cells (Supplementary Figure S4).
Figure 3 | Co-culture of RPE and immune cells induced activation of intracellular signaling leading to the phosphorylation of ERK1/2. ERK1/2 activation was
observed soon after 1 h of co-culture in ARPE-19 cells and was maintained up to 48 h (A-B); on the contrary, in Jurkat cells ERK1/2 phosphorylation was significantly
increased after 16 h and 24 h of co-culture (C-D). Representative Western blot images are shown (A and C) and the semiquantitative densitometric analysis of the
bands (B and D) is represented in the graphs (mean ± SD of four independent experiments); the amount of pERK1/2 is normalized to that of totERK1/2. *p < 0.05;
**p < 0.01; ***p < 0.001 versus ARPE-19/Jurkat (Newman−Keuls test after ANOVA).
Figure 4 | Effects of ARPE-19-Jurkat cells co-culture on IL-1β evaluated as mRNA levels. IL-1β expression was significantly increased in both ARPE-19 (A) and
Jurkat (B) cells after 16 h and 24 h of co-culture, respectively. The increment of IL-1β levels wasmaintained up to 48 h of co-culture. Data are expressed asmean ± SD of
four independent experiments carried out in triplicate. **p < 0.01; ***p < 0.001; ****p < 0.0001 versus ARPE-19/Jurkat (Newman−Keuls test after ANOVA).
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Overall, these data demonstrate the important role played by
integrins and adhesion molecules in the interactions between
RPE and immune cells.
Integrin Antagonists Could Disrupt
ARPE-19-Jurkat Interactions Via the
Modulation of Adhesion, Apoptosis/
Necrosis, MAPK Signaling Pathway and
IL-1β Expression
In previous studies we developed several ligands targeting
different types of integrin (De Marco et al., 2015; Tolomelli
et al., 2015; Baiula et al., 2016, Baiula et al., 2020; Dattoli
et al., 2018; Martelli et al., 2019). From the screening of a
small library of β-lactam derivatives that were specifically
designed by a structure-based strategy to target RGD-binding
or leukocyte integrin we obtained selective and potent integrin
ligands (Baiula et al., 2016). MN27 (compound 15 in (Baiula et al.,
2016)), which contains an aniline basic moiety, is a very potent
and selective αLβ2 integrin antagonist, able to reduce significantly
αLβ2-mediated cell adhesion and integrin-mediated intracellular
signaling pathway. SR714 (compound 4 in (Baiula et al., 2016)),
an azetidinone with a short carboxylic acid terminus, selectively
binds to α4β1 integrins and acts as an antagonist in cell adhesion
assays and intracellular signaling evaluation (Table 1). In another
study, we identified the compound named DS-70 that possesses a
linear sequence completed by o-methylphenylureaphenylacetyl
(MPUPA) and a simple glycine (Dattoli et al., 2018). The β-amino
acid in its structure contributed to stable conformation of the
overall structure and to increased serum stability. Through
pharmacological characterization, DS-70 was recognized as an
α4β1 antagonist with nanomolar potency: it prevented integrin-
mediated cell adhesion and antagonized VCAM-1-induced
degranulation of mast cells and eosinophils in vitro. Moreover,
in a dose-dependent manner, DS-70 significantly reduced the
clinical symptoms of allergic conjunctivitis as well as conjunctival
levels of chemokines and cytokines in a guinea pig model of
allergic conjunctivitis (Dattoli et al., 2018).
Figure 5 | Integrins and adhesion molecules involvement during co-culture of ARPE-19-Jurkat cells (A) Analysis of integrin expression on ARPE-19 cells evaluated
by flow cytometry. α5 integrin, VCAM-1 and ICAM-1 are significantly expressed on ARPE-19 cells; on the contrary ARPE-19 cells express low levels of α4, αL, αM, β1 and
β2 integrins. Data are expressed as mean fluorescence intensity (MFI) ± SD of four independent experiments carried out in triplicate. MFI values for respective isotype
control monoclonal antibody (mAb) were set to 0. Representative histograms are shown in Supplementary Figure 3. (B) Blocking VCAM-1 or ICAM-1, expressed
on ARPE-19 cells, or α4 integrin, expressed on Jurkat cells, using specific mAbs, significantly reduced the number of Jurkat cells adhered to ARPE-19 cells. Data are
expressed as mean ± SD of four independent experiments carried out in quadruplicate (C–D) The blockade of VCAM-1 or ICAM-1, expressed on ARPE-19 cells, or α4
integrin, expressed on Jurkat cells, using specificmAbs, prevented the activation of integrin-mediated intracellular signaling in ARPE-19 cells after 24 h of co-culture with
Jurkat cells. A representative western blot image is shown (C) and the semiquantitative densitometric analysis of the bands (D) is represented in the graph (mean ± SD of
four independent experiments); the amount of pERK1/2 is normalized to that of totERK1/2. **p < 0.01; ***p < 0.001; ****p < 0.0001 vs ARPE-19; ###p < 0.001 vs ARPE-
19 + Jurkat 24 h (Newman−Keuls test after ANOVA).
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To evaluate the possibility of exploiting integrin antagonists as
novel agents to treat dry AMD, MN27, SR714 and DS-70 were
employed in ARPE-19-Jurkat cells co-culture. Jurkat cells were
pre-treated with different concentrations of MN27, SR714 or DS-
70 (1–100 nM) for 30 min to block αLβ2 or α4β1 integrin
respectively. Thereafter, Jurkat cells were overlaid on ARPE-19
and co-cultured for 24 h; subsequently, ARPE-19 and Jurkat cells
were collected separately and analyzed. As shown in Figure 6,
integrin antagonists were able to significantly reduce apoptosis
levels in ARPE-19 cells co-cultured with Jurkat cells for 24 h.
Moreover, we found that the effect of DS-70 and MN27 was
concentration-dependent (Figure 6A and Supplementary
Figure S5). Integrin antagonists induced also a significant
reduction of necrosis levels after disrupting the interactions
between ARPE-19 and Jurkat cells. In contrast, we did not
observe any change in apoptosis or necrosis levels in Jurkat
co-cultured with ARPE-19 cells after the exposure to integrin
antagonists (data not shown). Regarding ARPE-19-Jurkat cell
adhesion, it was significantly reduced by pre-administering
integrin antagonists: blocking integrins expressed on ARPE-19
or Jurkat cells, MN27, SR714 or DS-70 strongly diminished Jurkat
cell adhesion to ARPE-19 cells (Figure 6C). As control
experiments, ARPE-19 cells were exposed to the vehicle
employed to dissolve integrin antagonists for 24 h; the vehicle,
a volume corresponding to the highest antagonist concentration,
did not induce apoptosis and necrosis in ARPE-19 cells, did not
influence Jurkat cell adhesion to ARPE-19 cells and did not
activate ERK1/2 intracellular signaling pathway in ARPE-19
cells (Supplementary Figure S6). The effects of integrin
antagonists were also investigated with regard to integrin-
mediated intracellular signaling activation. We found that
MN27, SR714 and DS-70 fully reverted the increase of ERK1/2
phosphorylation induced during ARPE-19-Jurkat cell co-culture
(Figure 7). It is intriguing to note that concentration-dependent
effect induced by integrin antagonists on intracellular signaling,
seen in Jurkat cells in previous studies (Baiula et al., 2016; Dattoli
et al., 2018), was not observed in ARPE-19 cells after the
interaction with Jurkat cells exposed to different
concentrations of DS-70, MN27 or SR714.
In addition, we observed that integrin antagonists prevented
the co-culture-induced increase in IL-1β expression both in
ARPE-19 and Jurkat cells induced by co-culture incubation
(Figure 8); this effect is concentration-dependent, especially in
ARPE-19 cells, in which the lowest concentration (1 nM) did not
exert any effect on IL-1β levels. The noncompetitive blocker of
ERK kinase PD 98059 (10 μM), added 30 min before overlaying
Jurkat to ARPE-19 cells, significantly reduced the co-culture-
induced up-regulation of IL-1β mRNA in both cell types
(Figure 8). Thus, confirming that ERK1/2 signaling
downstream of integrin activation is required for the up-
regulation of IL-1β mRNA.
DISCUSSION
In the retina there are two types of BRB: the inner barrier
comprises tight junctions of endothelial cells, whereas the
outer barrier is formed by tight junctions of RPE cells.
Therefore, RPE cells, together with retinal vasculature, limit
the entrance of blood component to the retina. Disease
conditions, including AMD (Miller et al., 1986), can lead to
disruption of BRB allowing inflammatory cells, platelets and
macromolecules to encounter RPE cells. In previous studies
contacts between RPE and mononuclear phagocyte
(Killingsworth et al., 1990; Van Der Schaft et al., 1993;
Penfold et al., 2001) or T cells have been described (Liversidge
et al., 1990; Devine et al., 1996). Moreover, RPE cells secrete a
multitude of cytokines and chemokines (Ablonczy et al., 2011;
Juel et al., 2012), contributing to the modulation of retinal
inflammation. In the present study we have characterized the
crosstalk between lymphocytes and RPE cells. We observed that
the interaction between ARPE-19 and Jurkat cells may induce
Figure 6 | Integrin antagonists MN27, SR714 and DS-70 (1–100 nM) prevented apoptosis (A) and necrosis (B) in ARPE-19 cells induced by 24 h of co-culture with
Jurkat cells. Cells not co-cultured and treated with the vehicle (DMSO) used to dissolve integrin antagonists were considered as reference (shown as ARPE-19 + vehicle
in the figure). Apoptosis and necrosis were measured by flow cytometry and the results are presented as the percentage of early apoptotic cells and late apoptotic/
necrotic cells. Values are mean ± SD from four experiments conducted in triplicate using different cell cultures (C) Integrin antagonists were also able to significantly
reduce Jurkat adhesion to ARPE-19 cells. Data are expressed as mean ± SD of four independent experiments. ***p < 0.001 vs ARPE-19; #p < 0.05; ##p < 0.01; ###p <
0.001 vs ARPE-19 + Jurkat 24 h (Newman-Keuls test after ANOVA).
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ARPE-19 cells apoptosis and necrosis, suggesting a potential role
of inflammatory cells recruited at the BRB in RPE disruption
observed in retinal disease conditions. It was previously
demonstrated that RPE death can be due to necroptosis
(Hanus et al., 2015) and that preventing this phenomenon
could be beneficial for patients suffering from AMD. In
addition, we found an increased expression of IL-1β in both
RPE cells and lymphocytes after 16 and 24 h of co-culture,
respectively. These data suggest that the physical interaction
between RPE and lymphocytes could trigger and sustain an
inflammatory reaction mediated by elevated levels of pro-
inflammatory mediators produced by both cell types. IL-1β
has important homeostatic functions but is also implicated in
pathophysiological changes that occur during inflammatory
disease conditions. As a matter of fact, IL-1β can be
considered as a marker of inflammation (Lopez-Castejon and
Brough, 2011) and is known to be involved in AMD pathogenesis.
Accordingly, proinflammatory cytokines, including IL-1 β,
maybe partly responsible of RPE death and photoreceptor
degeneration (Kauppinen et al., 2012; Wang and Hartnett,
2016). In the eye of patients with AMD, augmented levels of
inflammatory cytokines and chemokines have been reported in
peripheral blood circulation (Jonas et al., 2010, Jonas et al., 2012).
Moreover, previous studies showed that both immune cells
(Doyle et al., 2012) and RPE cells (Fukuoka et al., 2003;
Kauppinen et al., 2012) are able to produce IL-1β.
Furthermore, to better characterize RPE cell-lymphocyte
interaction, we evaluated VCAM-1 and ICAM-1 levels, being
these two adhesion molecules involved in immune cells
recruitment to inflamed tissues. After ARPE-19-Jurkat co-
culture, ICAM-1 expression was significantly reduced in
ARPE-19 cells, whereas VCAM-1 levels were unaffected.
VCAM-1 and ICAM-1 are endogenous ligands for α4β1 and
αLβ2 integrin, respectively. Previous studies have shown that
the binding between adhesion molecules and integrins may
contribute to the interaction between RPE and immune cells
(Mesri et al., 1994; Devine et al., 1996; Holtkamp et al., 2001). The
data reported in the present study confirm the contribution of
integrins in immune cells recruitment to RPE. Accordingly, the
adhesion of Jurkat cells to ARPE-19 is mediated by both α4β1 and
αLβ2 integrins and subsequently we observed integrin-mediated
intracellular signaling activation. These results were confirmed by
using blocking antibodies directed against α4β1, αLβ2 integrins, or
adhesion molecules VCAM-1 or ICAM-1. Blocking antibodies
were able to reduce Jurkat cell adhesion to ARPE-19 and prevent
the activation of integrin-mediated ERK1/2 intracellular pathway.
Integrins are heterodimeric transmembrane receptors, that
mediate cell-to-cell and cell-to-extracellular matrix adhesion
(ECM) and are considered valuable therapeutic target for the
development of new drugs. Particularly, drugs targeting leukocyte
integrins, mainly α4β1 and α4β7, have proven to be effective for the
treatment of inflammatory conditions, including ulcerative
colitis, Crohn’s disease, multiple sclerosis (Bamias et al., 2013;
Lobatõn et al., 2014; Baiula et al., 2019). Regarding ocular diseases
involving inflammation, lifitegrast, an αLβ2integrin antagonist,
has been recently approved and is a safe and effective treatment
for dry eye disease (DED) (Haber et al., 2019). Lifitegrast binds
competitively to the αL integrin subunit preventing the adhesion,
migration and proliferation of lymphocytes and the subsequently
cytokine production, thereby reducing the symptoms of DED
(Kelly et al., 2007; Guimaraes De Souza et al., 2018). Moreover,
GW559090, a potent α4 integrin antagonist, has been proposed
for the treatment of dry eye disease (Krauss et al., 2015) and for
Sjögren’s syndrome associated dry eye (Contreras-Ruiz et al.,
2016). In addition, the importance of integrins in the
pathogenesis of ocular diseases is demonstrated by the
possibility to target RGD integrins, such as αvβ3, αvβ5 and
α5β1, expressed on endothelial cells and on RPE. RGD
integrins mediate mainly interactions with ECM, and RGD
integrin antagonists were shown to prevent the migration of
Figure 7 | Integrin antagonists MN27, SR712 and DS-70 (1–100 nM)
were able to significantly prevent integrin-mediated activation of intracellular
signaling in ARPE-19 after 24 h of co-culture with Jurkat cells. ERK1/2
phosphorylation was induced during ARPE-19-Jurkat cells co-culture;
on the contrary, integrin antagonists significantly reduced ERK1/2 activation.
Representative western blot images are shown (A-B) and the semiquantitative
densitometric analysis of the bands (C) is represented in the graphs (mean ±
SD of four independent experiments); the amount of pERK1/2 is normalized to
that of totERK1/2. ***p < 0.001 vs ARPE-19; ###p< 0.001 vs ARPE-19 +
Jurkat 24 h (Newman−Keuls test after ANOVA).
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endothelial cells and thereby neovascularization (Hu et al., 2019)
and to counteract choroidal angiogenesis and vascular leakage
(Yasukawa et al., 2004). Therefore, antagonists targeting RGD
integrins may be valuable in ocular diseases involving
neovascularization, as in wet AMD.
In a previous study we have reported the pharmacological
characterization of DS-70, a potent and selective α4β1 integrin
antagonist, in vitro and in vivo in a guinea pig model of allergic
conjunctivitis (Dattoli et al., 2018). As a selective antagonist of
α4β1, DS-70 prevented integrin-mediated cell adhesion, ERK1/
2 phosphorylation and mast cells and eosinophils
degranulation in vitro. Moreover, DS-70 significantly
reduced clinical symptoms of ocular inflammation, α4β1
expressing cell recruitment to the conjunctiva and pro-
inflammatory cytokine and chemokine levels in a guinea pig
model of allergic conjunctivitis. Within this frame, in the
present study we investigated the effects elicited by DS-70
and other leukocyte integrin antagonists (namely MN27 and
SR714) on RPE-lymphocyte crosstalk. MN27 and SR714 are
β-lactam derivatives that behave as αLβ2 and α4β1 antagonists,
respectively (Baiula et al., 2016). All three integrin antagonists
employed in this study interfere with ARPE-19-Jurkat cells
interaction by blocking αLβ2 or α4β1, they significantly reduce
cell adhesion, activation of integrin-mediated intracellular
signaling and expression of pro-inflammatory cytokine IL-
1β. Moreover, DS-70, MN27 and SR714 significantly prevent
apoptosis and necrosis induced in ARPE-19 cells by interaction
with Jurkat cells. The disruption of RPE-lymphocyte crosstalk
caused by integrin antagonists could be important for the
treatment of dry AMD as it reduces RPE cell death and
reduced inflammasome activation. These preliminary results
provide further support to the hypothesis that αLβ2 or α4β1
integrin can be considered as valuable drug targets in retinal
diseases and that the integrin antagonists employed in the
present study could be useful to develop new therapeutic
agents useful to fight dry AMD.
The in vitro model employed in the current study rely on
ARPE-19 cells, a spontaneously immortalized RPE cell line
widely used to evaluate RPE function. ARPE-19 cell line
represents a simplified cell culture model to study RPE cell
functions in vitro and displays some differences respect to
primary RPE, such as little or no pigmentation, variable
morphology and weaker tight junctions; due to these
properties ARPE-19 cells rather resemble aged eye or
pathological conditions-affected RPE cells (Ablonczy et al.,
2011). The current investigation is a preliminary research
aimed at studying the involvement of integrins in RPE-
immune cells interaction in AMD and the potential use of
integrin antagonists within this frame. To confirm data
obtained in the current study other in vitro cell culture
models, including polarized human RPE cells (Khristov
et al., 2018) and 3D cultured models (Forest et al., 2015;
Shokoohmand et al., 2017; Schnichels et al., 2020) should be
further employed. Animal models recapitulating several aspects
of AMD are needed to further validate results obtained in vitro
models. Nonetheless, our findings demonstrate for the first
time the involvement of α4β1 and αLβ2 integrins in the
pathophysiology of AMD; thus, pointing at integrin
antagonists as promising drug candidates to be further
characterized.
In conclusion, integrin antagonists could protect RPE cells
from death induced by leukocytes recruited to the retina as they
downregulate proinflammatory cytokine expression, reduce
ERK1/2 signaling and thereby resulting in the inhibition of
the inflammation process. Nevertheless, further studies are
needed to better characterize the effects of integrin
Figure 8 | Effects of integrin antagonists on IL-1β expression in ARPE-19-Jurkat cells after 24 h of co-culture with Jurkat cells. IL-1β expression, significantly
increased in both ARPE-19 (A) and Jurkat cells (B) after 24 h of co-culture, was significantly reduced by integrin antagonists MN27, SR714 and DS-70 in both ARPE-19
and Jurkat cells. PD 98059 (10 μM), an ERK1/2 signaling inhibitor pre-incubated with the cells 30 min before starting the co-culture, prevented IL-1β expression
increment both in ARPE-19 and Jurkat cells. Data are expressed as mean ± SD of four independent experiments. ***p < 0.001 versus ARPE-19/Jurkat; #p < 0.05;
##p < 0.01; ###p < 0.001 vs ARPE-19 + Jurkat 24 h/Jurkat 24 h (Newman−Keuls test after ANOVA).
Frontiers in Pharmacology | www.frontiersin.org January 2021 | Volume 11 | Article 61783611
Baiula et al. Integrin Antagonists to Treat AMD
antagonists in more complex in vitro models and in animal
models of AMD.
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